Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Menghan Liu, Xiaoqi Qin, Weiwei Tian, Yuechen Zhang, Yanru Zhang, Lefu Huang, Wenjing Li, Jingrong Wang, Yanping Ma, Liping Su, Yan Yan, Aijun Liao, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2025-2280

Published: 2025

Journal Articles

Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study

Jing Chen, Donghua He, Xiaoyan Han, Mingming Zhang, Li Yang, Haimeng Yan, Lai Jin, He Huang, Juan Du, Aijun Liu, Zhen Cai

Blood (2025) 146 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2025-2276

Published: 2025

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

Xiaozhe Li, Baijun Fang, Di Wang, Yuzhang Liu, Yanping Ma, Peiling Zhang, Aijun Liu, Wenming Chen, Juan Li

Blood (2025) 146 (Supplement 1): 7580.

https://doi.org/10.1182/blood-2025-7580

Published: 2025

Journal Articles

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Lefu Huang, Yuechen Zhang, Huijuan Wang, Wenjing Li, Yanru Zhang, Menghan Liu, Ying Tian, Zunmin Zhu, Hong-Hu Zhu, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 7576.

https://doi.org/10.1182/blood-2025-7576

Published: 2025

Journal Articles

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Qiling Bu, Yiwen Jiang, Jingjing Deng, Ping Wang, Zhiyao Zhang, Guangzhong Yang, Ying Tian, Wen Gao, Aijun Liu, Leng Yun, Yin Wu, Wenming Chen, Honghu Zhu

Blood (2025) 146 (Supplement 1): 7564.

https://doi.org/10.1182/blood-2025-7564

Published: 2025

Journal Articles

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin WU, Chuanying Geng, Aijun Liu, Lefu Huang, Leng Yun, Yanru Zhang, Ying Tian, jing jia, Menghan Liu, Huijuan Wang, Guangzhong Yang, Hong-Hu Zhu, Wenming Chen, Wen Gao

Blood (2025) 146 (Supplement 1): 7590.

https://doi.org/10.1182/blood-2025-7590

Published: 2025

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome, Proteasome Inhibitors, Pomalidomide and Dexamethasone Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma in China

Menghan Liu, Jigang Wang, Haiguo Zhang, Ying Tian, Hongming Huang, Yan Wang, Qing Leng, Wenming Chen, Aijun Liu

Blood (2024) 144 (Supplement 1): 7072.

https://doi.org/10.1182/blood-2024-210174

Published: 2024

Journal Articles

The Efficacy and Safety of Zanubrutinib, Dexamethasone and or Not Cyclophosphamide Regimen in Symptomatic Waldenstrom Macroglobulinnemia

Aijun Liu, Jin Lu, Yanping Ma, Da Gao, Luoming Hua, Yuechen Zhang, Chuanying Geng, Ying Tian, Yun Leng, Wenming Chen

Blood (2023) 142 (Supplement 1): 6699.

https://doi.org/10.1182/blood-2023-189130

Published: 2023

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Aijun Liu, Rong Fu, PhD, Zunmin Zhu, Li Bao, MD, Huizheng Bao, Da Gao, MD, Yanping Ma, PhD, Chen Wenming, MD, Hong Yu

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139064

Published: 2020

Journal Articles

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Shenmiao Yang, MD, Aijun Liu, MD, Yuping Zhong, MD, Xiaojun Huang, MDPhD, Wenming Chen, MD, Jin Lu

Blood (2015) 126 (23): 4247.

https://doi.org/10.1182/blood.V126.23.4247.4247

Published: 2015

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Mitoxantrone Hydrochloride Liposome, Proteasome Inhibitors, Pomalidomide and Dexamethasone Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma in China

The Efficacy and Safety of Zanubrutinib, Dexamethasone and or Not Cyclophosphamide Regimen in Symptomatic Waldenstrom Macroglobulinnemia

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study

Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only